2013
DOI: 10.7705/biomedica.v34i1.1446
|View full text |Cite
|
Sign up to set email alerts
|

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012

Abstract: Introduction: New tyrosine kinase inhibitor treatments for chronic myeloid leukemia based on nilotinib, dasatinib and imatinib have improved patient quality of life and have turned chronic myeloid leukemia from a fatal disease into a chronic disease. Objective: To evaluate the cost-effectiveness of nilotinib, 600 mg, and dasatinib, 100 mg, each compared to imatinib, 400 mg, as first-line therapy in chronic myeloid leukemia in Colombia from a third-party payer's perspective. Materials and methods: A cost-effect… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 15 publications
references
References 16 publications
0
0
0
Order By: Relevance